Maria Stepanova
Maria Stepanova
Research Investigator, Inova Health System
Bestätigte E-Mail-Adresse bei
Zitiert von
Zitiert von
Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008
ZM Younossi, M Stepanova, M Afendy, Y Fang, Y Younossi, H Mir, ...
Clinical gastroenterology and hepatology 9 (6), 524-530. e1, 2011
The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe
ZM Younossi, D Blissett, R Blissett, L Henry, M Stepanova, Y Younossi, ...
Hepatology 64 (5), 1577-1586, 2016
Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver‐related mortality
ZM Younossi, M Stepanova, N Rafiq, H Makhlouf, Z Younoszai, ...
Hepatology 53 (6), 1874-1882, 2011
Adipokines and cytokines in non‐alcoholic fatty liver disease
MH Jarrar, A Baranova, R Collantes, B Ranard, M Stepanova, C Bennett, ...
Alimentary pharmacology & therapeutics 27 (5), 412-421, 2008
Nonalcoholic fatty liver disease in lean individuals in the United States
ZM Younossi, M Stepanova, F Negro, S Hallaji, Y Younossi, B Lam, ...
Medicine 91 (6), 319-327, 2012
Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates
Z Younossi, M Stepanova, JP Ong, IM Jacobson, E Bugianesi, A Duseja, ...
Clinical gastroenterology and hepatology 17 (4), 748-755. e3, 2019
Extrahepatic manifestations of hepatitis C: a meta-analysis of prevalence, quality of life, and economic burden
Z Younossi, H Park, L Henry, A Adeyemi, M Stepanova
Gastroenterology 150 (7), 1599-1608, 2016
Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population
M Stepanova, ZM Younossi
Clinical Gastroenterology and Hepatology 10 (6), 646-650, 2012
Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease
N Hossain, A Afendy, M Stepanova, F Nader, M Srishord, N Rafiq, ...
Clinical Gastroenterology and Hepatology 7 (11), 1224-1229. e2, 2009
A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH)
ZM Younossi, M Jarrar, C Nugent, M Randhawa, M Afendy, M Stepanova, ...
Obesity surgery 18, 1430-1437, 2008
Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study
M Stepanova, N Rafiq, ZM Younossi
Gut 59 (10), 1410-1415, 2010
Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD)
M Stepanova, N Rafiq, H Makhlouf, R Agrawal, I Kaur, Z Younoszai, ...
Digestive diseases and sciences 58, 3017-3023, 2013
Epidemiology of chronic liver diseases in the USA in the past three decades
ZM Younossi, M Stepanova, Y Younossi, P Golabi, A Mishra, N Rafiq, ...
Gut 69 (3), 564-568, 2020
In-hospital mortality and economic burden associated with hepatic encephalopathy in the United States from 2005 to 2009
M Stepanova, A Mishra, C Venkatesan, ZM Younossi
Clinical gastroenterology and hepatology 10 (9), 1034-1041. e1, 2012
Non‐alcoholic fatty liver disease (NAFLD) is associated with low level of physical activity: a population‐based study
L Gerber, M Otgonsuren, A Mishra, C Escheik, A Birerdinc, M Stepanova, ...
Alimentary pharmacology & therapeutics 36 (8), 772-781, 2012
Nonalcoholic steatohepatitis is the most rapidly increasing indication for liver transplantation in the United States
ZM Younossi, M Stepanova, J Ong, G Trimble, S AlQahtani, I Younossi, ...
Clinical Gastroenterology and Hepatology 19 (3), 580-589. e5, 2021
Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir
ZM Younossi, M Stepanova, N Afdhal, KV Kowdley, S Zeuzem, L Henry, ...
Journal of hepatology 63 (2), 337-345, 2015
A biomarker panel for non-alcoholic steatohepatitis (NASH) and NASH-related fibrosis
ZM Younossi, S Page, N Rafiq, A Birerdinc, M Stepanova, N Hossain, ...
Obesity surgery 21, 431-439, 2011
Associations of chronic hepatitis C with metabolic and cardiac outcomes
ZM Younossi, M Stepanova, F Nader, Z Younossi, E Elsheikh
Alimentary pharmacology & therapeutics 37 (6), 647-652, 2013
Predictors of health‐related quality of life in patients with chronic liver disease
A Afendy, JB Kallman, M Stepanova, Z Younoszai, RD Aquino, G Bianchi, ...
Alimentary pharmacology & therapeutics 30 (5), 469-476, 2009
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20